A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update.
European Journal of Cancer.
Times cited: 274
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial.
Journal of Clinical Oncology.
Times cited: 1757